Comparative Pharmacology
Head-to-head clinical analysis: JASCAYD versus OFEV.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JASCAYD versus OFEV.
JASCAYD vs OFEV
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JASCAYD (tasquinimod) is a selective allosteric inhibitor of S100A9, which binds to toll-like receptor 4 (TLR4) and receptor for advanced glycation end-products (RAGE). It modulates the tumor microenvironment by inhibiting myeloid-derived suppressor cell (MDSC) recruitment and function, reducing angiogenesis, and enhancing anti-tumor immune responses.
Nintedanib is a tyrosine kinase inhibitor that blocks the activity of fibroblast growth factor receptor (FGFR), platelet-derived growth factor receptor (PDGFR), and vascular endothelial growth factor receptor (VEGFR), thereby inhibiting fibroblast proliferation, migration, and transformation, and reducing extracellular matrix deposition.
Adults: 300 mg orally twice daily with food.
150 mg orally twice daily, taken with food.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours; clinically relevant for once-daily dosing.
Terminal elimination half-life is approximately 38 hours (range 30–48 hours) at steady state, supporting once-daily dosing.
Primarily renal excretion (80%) as unchanged drug; 20% fecal via biliary elimination.
Primarily biliary/fecal (~93.4% of total radioactivity recovered in feces), renal excretion is minor (~0.6% unchanged in urine).
Category C
Category C
Tyrosine Kinase Inhibitor
Tyrosine Kinase Inhibitor